Literature DB >> 6366068

Acid treatment enhances IL-2 activity of conditioned medium.

B J Mills, P S Mitsky, C W Todd.   

Abstract

Although conditioned medium (CM) from human lymphocytes or mononuclear cells is the most readily available source of interleukin-2 (IL-2) for human T cell culture, its IL-2 activity in our experience is inconsistent. It is likely that this is, at least in part, due to the presence of toxic substances in the CM. Using CM from TPA/SEA induced human mononuclear cells, we have found that acid treatment (pH 2.0, greater than 30 min) significantly improves its ability to promote T cell growth. It is postulated that the selection process which occurs in cultures of mitogen stimulated T cells may result in cells which are sensitive to mitogen-induced lymphotoxins and that these are inactivated by the acid treatment. Since acid treatment did not similarly improve the T cell growth promoting ability of PHA induced, lectin-free commercial IL-2, there must be other differences between it and our CM, which play a role in T cell growth.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6366068     DOI: 10.1016/0022-1759(84)90086-3

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  3 in total

1.  Autocrine growth inhibition of a cloned line of helper T cells.

Authors:  J B Horowitz; J Kaye; P J Conrad; M E Katz; C A Janeway
Journal:  Proc Natl Acad Sci U S A       Date:  1986-03       Impact factor: 11.205

2.  The analysis of an anti-fluorescein response at limit dilution: the effect of lymphokine preparations on the apparent specificity.

Authors:  M A Skinner; R Prestidge; J Marbrook
Journal:  Immunology       Date:  1985-07       Impact factor: 7.397

3.  Synergy between interleukin-2 and a second factor in the long-term growth of human T cells.

Authors:  B J Mills; J E Shively; P S Mitsky; D H Hawke; S J Forman; C L Wright; C W Todd
Journal:  Immunology       Date:  1986-09       Impact factor: 7.397

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.